Andere Sprachen Neurocrine Biosciences, Inc.

Aktien

900964

US64125C1099

NBIX

Markt geschlossen - Nasdaq Andere Börsenplätze 22:00:00 25.04.2024			% 5 Tage	% 1. Jan.
137.8 ^USD	-0.87%		+3.94%	+4.55%

24.04.	NEUROCRINE BIOSCIENCES, INC. : Von Wells Fargo Securities zum Kaufen aufgerüstet	ZM
24.04.	Neurocrine Biosciences, Inc. startet die What the C@H! Bildungsinitiative zur Unterstützung der Gemeinschaft für kongenitale Nebennierenhyperplasie	CI

Andere Sprachen

Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!

100% kostenlose Registrierung

Neurocrine Biosciences Launches WHAT THE C@H Educational Initiative to Support Congenital Adrenal Hyperplasia Community	25.04.
Neurocrine Biosciences, Inc. Launches What the C@H! Educational Initiative to Support Congenital Adrenal Hyperplasia Community	24.04.
Neurocrine Biosciences, Inc. Reports Positive Phase 2 Data for NBI-1065845 in Adults with Major Depressive Disorder	23.04.
Nxera Pharma's Neuro Drug NBI-1117568 Passed Preclinical Toxicity Test	17.04.
Neurocrine Biosciences, Sentia Medical Sciences Extend Partnership on Prospective Drug Development	16.04.
Sentia Medical Sciences and Neurocrine Biosciences Extend Research Collaboration to Discover Novel CRF Peptides	16.04.
Sentia Medical Sciences Inc. and Neurocrine Biosciences, Inc. Extend Research Collaboration to Discover Novel CRF Peptides	16.04.
Neurocrine Biosciences Announces Conference Call and Webcast of First Quarter 2024 Financial Results	10.04.
Neurocrine Biosciences Doses First Patient in Phase 2 Depressive Disorder Study	03.04.
Neurocrine Biosciences Announces First-Patient Dosed in Phase 2 Clinical Study Evaluating NBI-1070770 in Adults with Major Depressive Disorder	03.04.
Neurocrine Biosciences, Inc. Announces First-Patient Dosed in Phase 2 Clinical Study Evaluating NBI-1070770 in Adults with Major Depressive Disorder	03.04.
Neurocrine Biosciences Starts Phase 1 Trial of Investigational Neuropsychiatric Drug	28.03.
Neurocrine Biosciences Announces Initiation of Phase 1 Clinical Study Evaluating Effects of NBI-1065890, a Second-Generation VMAT2 Inhibitor, in Healthy Adults	28.03.
Neurocrine Biosciences Announces Initiation of Phase 1 Clinical Study Evaluating Effects of NBI-1065890, a Second-Generation VMAT2 Inhibitor, in Healthy Adults	28.03.
Neurocrine Biosciences Insider Sold Shares Worth $5,576,710, According to a Recent SEC Filing	15.03.
Neurocrine Biosciences Insider Sold Shares Worth $420,419, According to a Recent SEC Filing	15.03.
Neurocrine Biosciences to Participate at Virtual Investor Conferences in March	11.03.
Neurocrine Biosciences Insider Sold Shares Worth $922,632, According to a Recent SEC Filing	01.03.
Neurocrine Biosciences Insider Sold Shares Worth $1,085,388, According to a Recent SEC Filing	01.03.
Neurocrine Biosciences to Participate at Investor Conferences in March	27.02.

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen Neurocrine Biosciences, Inc.

Aktien

900964

US64125C1099

NBIX

Andere Sprachen

Filter